A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
Gary Richardson(Cabrini Hospital), Xunwei Dong, Ya-Li Lee(Sangamo BioSciences (United States)), Hirva Mamdani(Wayne State University), Stephen K. Williamson(The University of Kansas Cancer Center), Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center), Xingli Wang(Jilin University), Joaquina Baranda(The University of Kansas Cancer Center), Anis Hamid(Harvard University), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Li Li(Shanghai Jiao Tong University), Nitika Nitika(University of North Carolina at Charlotte)
Cited by 5
Related Papers
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373